Home > Dermatology > AAD 2019 > Psoriasis and Biologics: The Beat Goes On > Psoriasis and Biologics: The Beat Goes On

Psoriasis and Biologics: The Beat Goes On

Prof. Mark Lebwohl, Mount Sinai School of Medicine, USA
AAD 2019

With an increasing number of biologics to treat moderate-to-severe psoriasis, selection of the right drug becomes a real challenge for every dermatologist. Therapy should be guided by comorbidities but also by individual patient preferences. Novel drugs are not only more effective but also safer than conventional immunosuppressive drugs.

At present, there are numerous treatment possibilities for psoriasis. But does one choose the right agent? Selection of therapy has to take comorbidities into account. “The first question, I ask my patients is, do you have joint pain?” said Prof. Mark Lebwohl (Mount Sinai School of Medicine, USA) [1]. All tumour necrosis factor alpha (TNF-α) blockers are also effective in psoriatic arthritis (PsA). Other treatment possibilities are ustekinumab, apremilast, and the IL-17 blockers secukinumab, ixekizumab, and brodalumab.

Higher risk of non-melanoma skin cancer with TNF-alpha blockers

The correl...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on